Skin & Aesthetic Medicine
Cosmetic peptides represent the segment with the most consumer marketing and the most variable evidence quality. GHK-Cu is 503A-listed with peer-reviewed clinical trials. Matrixyl/Argireline have published RCTs. Many others have no peer-reviewed human data.
Relevant Peptides
503A listed; peer-reviewed RCTs for skin rejuvenation.
Free peptide; wound healing and anti-inflammatory.
Published double-blind RCTs; wrinkle reduction documented.
Published RCTs; SNARE inhibition; expression wrinkle reduction.
Synergistic with Argireline; limited independent data.
Manufacturer-funded studies; independent validation limited.
Hair growth; limited clinical data.
The Evidence Tier System for Cosmetic Peptides
Tier 1 (Peer-reviewed RCTs):
- GHK-Cu: Published, double-blind human RCTs
- Matrixyl: Published, double-blind human RCTs
- Argireline: Published, double-blind human RCTs
Tier 2 (Plausible mechanism, limited human data):
- GHK (free), Leuphasyl, AHK-Cu
Tier 3 (Manufacturer data, no independent replication):
- SNAP-8, most “proprietary” cosmetic peptides
The 503A Advantage
GHK-Cu’s 503A listing provides a legal, regulated compounding path. This regulatory recognition implicitly validates its safety profile and enables formulations with certified ingredient quality — a meaningful quality assurance advantage over unregulated cosmetic sources.
Stay current on peptide evidence
Weekly regulatory updates and study breakdowns. Free.